STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
publication date
- January 1, 2021
published in
- Human cell Journal
has subject area
- Antineoplastic Agents
- Apoptosis
- Benzofurans
- Cell Line, Tumor
- Cell Movement
- Drug Resistance, Neoplasm
- Drug Synergism
- ErbB Receptors
- Gefitinib
- Gene Expression
- Gene Expression Regulation, Neoplastic
- Humans
- Lung Neoplasms
- Multidrug Resistance-Associated Proteins
- Mutation
- Naphthoquinones
- Neoplasm Invasiveness
- Protein Kinase Inhibitors
- Receptor Tyrosine Kinase-like Orphan Receptors
- STAT3 Transcription Factor
- Signal Transduction
- Tumor Suppressor Protein p53